

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this joint announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this joint announcement.*

*This joint announcement is for information purposes only and does not constitute, or form part of, an invitation or offer to acquire, purchase or subscribe for securities of Guanze Medical Information Industry (Holding) Co., Ltd. or the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of securities of Guanze Medical Information Industry (Holding) Co., Ltd. in any jurisdiction in contravention of applicable laws or regulations. This joint announcement is not for release, publication or distribution in or into any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction.*

**FUNDE (HONG KONG) INVESTMENT  
HOLDINGS CO., LIMITED**

富德(香港)投資控股有限公司  
(Incorporated in Hong Kong with limited liability)

**GUANZE MEDICAL INFORMATION  
INDUSTRY (HOLDING) CO., LTD.**

(Incorporated in the Cayman Islands with limited liability)  
(Stock Code: 2427)

## **JOINT ANNOUNCEMENT**

**DELAY IN DESPATCH OF COMPOSITE DOCUMENT  
RELATING TO MANDATORY UNCONDITIONAL CASH OFFER  
BY ARISTO SECURITIES LIMITED  
FOR AND ON BEHALF OF  
FUNDE (HONG KONG) INVESTMENT HOLDINGS CO., LIMITED  
TO ACQUIRE ALL THE ISSUED SHARES OF  
GUANZE MEDICAL INFORMATION  
INDUSTRY (HOLDING) CO., LTD.  
(OTHER THAN THOSE ALREADY OWNED AND/OR  
AGREED TO BE ACQUIRED BY  
FUNDE (HONG KONG) INVESTMENT HOLDINGS CO., LIMITED,  
ITS ULTIMATE BENEFICIAL OWNERS  
AND PARTIES ACTING IN CONCERT WITH ANY OF THEM)**

Financial adviser to the Offeror



Financial adviser to the Company



Independent Financial Adviser to the Independent Board Committee

 軟庫中華 **SBI China**

Reference is made to the joint announcements dated 11 February 2026 and 20 February 2026 (collectively, the “**Joint Announcements**”) issued by the Offeror and the Company in relation to, among others, the Sale and Purchase Agreement and the Offer. Unless otherwise stated, capitalised terms used in this joint announcement shall have the same meanings as those defined in the Joint Announcements.

## **DELAY IN DESPATCH OF THE COMPOSITE DOCUMENT**

As disclosed in the Joint Announcements, it is the intention of the Offeror and the Board to combine the offer document and the offeree board circular into the Composite Document. Pursuant to Rule 8.2 of the Takeovers Code, the Composite Document in connection with the Offer setting out, among other things, (i) details of the Offer (including the expected timetable and the terms of the Offer); (ii) a letter of recommendation from the Independent Board Committee to the Independent Shareholders in respect of the Offer; and (iii) a letter of advice from the Independent Financial Adviser to the Independent Board Committee in respect of the Offer, together with the Form of Acceptance, should be despatched to the Shareholders, no later than 21 days after the date of the Joint Announcement dated 11 February 2026, i.e. on or before 4 March 2026, unless the Executive grants a consent for extension.

As additional time is required for preparing and finalising certain information in the Composite Document (including but not limited to the audited financial information of the Company for the year ended 31 December 2025, which is expected to be published by the Company on 31 March 2026), an application has been made to the Executive pursuant to Rule 8.2 of the Takeovers Code for the Executive’s consent to extend the deadline for the despatch of the Composite Document from 4 March 2026 to a date falling on or before 10 April 2026, and the Executive has indicated that it is minded to grant such consent.

Further announcement(s) will be jointly made by the Offeror and the Company when the Composite Document (together with the relevant Form of Acceptance) is despatched or in the event of any changes to the expected timetable.

By order of the board  
**FUNDE (HONG KONG) INVESTMENT  
HOLDINGS CO., LIMITED**  
**Zhang, David Jia-yuan**  
*Sole director*

By order of the Board  
**Guanze Medical Information  
Industry (Holding) Co., Ltd.**  
**Meng Xianzhen**  
*Chairman and executive Director*

Hong Kong, 4 March 2026

*As at the date of this joint announcement, Mr. Zhang is the sole director of the Offeror. As at the date of this joint announcement, Mr. Cheung is the sole director of Shenzhen City Junde Investment Co., Ltd.\* (深圳市峻德投資有限公司), the ultimate parent company of the Offeror.*

*Each of the sole director of the Offeror (being Mr. Zhang) and the sole director of the ultimate parent company of the Offeror (being Mr. Cheung) jointly and severally accepts full responsibility for the accuracy of the information contained in this joint announcement (other than the information relating to the Group, the Selling Shareholder and its ultimate beneficial owner), and confirms, having made all reasonable enquiries, that to the best of his knowledge, opinions expressed in this joint announcement (other than those expressed by the Directors in their capacities as such) have been arrived at after due and careful consideration and there are no other facts not contained in this joint announcement, the omission of which would make any statement in this joint announcement misleading.*

*As at the date of this joint announcement, the Board comprises Mr. Meng Xianzhen (Chairman) and Mr. Guo Zhenyu as executive Directors, Ms. Meng Cathy as non-executive Director, and Dr. Zhao Bin, Dr. Chang Shiwang and Dr. Wong Man Hin Raymond as independent non-executive Directors.*

*The Directors jointly and severally accept full responsibility for the accuracy of the information contained in this joint announcement (other than the information relating to the Offeror, the ultimate beneficial owners of the Offeror and the parties acting in concert with any of them), and confirm, having made all reasonable enquiries, that to the best of their knowledge, opinions expressed in this joint announcement (other than those expressed by each of the sole director of the Offeror and the sole director of the ultimate parent company of the Offeror) have been arrived at after due and careful consideration and there are no other facts not contained in this joint announcement, the omission of which would make any statement in this joint announcement misleading.*

*In the event of any inconsistencies, the English text of this joint announcement shall prevail over its Chinese text.*

*\* For identification purpose only*